Purple Biotech (PPBT) Operating Expenses (2014 - 2026)

Purple Biotech (PPBT) has 12 years of Operating Expenses data on file, last reported at $2.3 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $2.3 million, up 59.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 million (up 0.59% YoY), and the FY2025 annual result was $27.5 million, up 149.5% from the prior year.
• Operating Expenses retreated to $2.3 million in Q1 2026 per PPBT's latest filing, from $3.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $7.4 million in Q1 2022 and troughed at $1.1 million in Q4 2024.
• A 5-year average of $3.9 million and a median of $3.6 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses slumped 83.28% in 2024, then jumped 185.7% in 2025.
• A 5-year view of Operating Expenses shows it stood at $6.7 million in 2022, then fell by 5.05% to $6.3 million in 2023, then tumbled by 83.28% to $1.1 million in 2024, then jumped by 185.7% to $3.0 million in 2025, then fell by 23.24% to $2.3 million in 2026.
• Business Quant data shows PPBT's Operating Expenses at $2.3 million in Q1 2026, $3.0 million in Q4 2025, and $1.4 million in Q3 2025.